Saxagliptin (BMS477118; Onglyza)

Description: Saxagliptin (formerly also known as BMS-477118; brand name: Onglyza) is a potent, orally bioactive, selective and reversible DPP-4 (dipeptidyl peptidase-4) inhibitor with potential anti-hyperglycemic activity. It inhibits DPP-4 with an IC50 of 26 nM. Saxagliptin was approved in 2008 by FDA for the treatment of type 2 diabetes. In vitro, saxagliptin inhibits FBS-, insulin- and IGF1-induced ERK phosphorylation and cell proliferation, in both MSC and MC3T3E1 preosteoblasts. In the absence of growth factors, saxagliptin has no effect on ERK activation or cell proliferation.

References: Adv Ther. 2009 Mar; 26(3):249-62; J Med Chem. 2005 Jul 28; 48(15):5025-37.

Related CAS: 1073057-20-1 (HCl hydrate); 361442-04-8 (free base); 945667-22-1 (hydrate); 709031-78-7 (HCl); 1073057-33-6 (benzoate hydrate)

Chemical Name: (1S, 3S, 5S)-2-((S)-2-amino-2-((1r, 3R, 5R, 7S)-3-hydroxyadamantan-1-yl)acetyl)-2-azabicyclo[3.1.0]hexane-3-carbonitrile

SMILES Code: N#C[CH]1C[C]2([H])[C](C2)([H])N1C([CH]([C]34C[CH]5C[CH](C4)C[C](C5)(O)C3)N)=O